Partial Prostate Salvage High Dose Rate Brachytherapy

Recurrent Prostate Cancer Clinical Trial

— SalvageHDR  

Official title:

High Dose Rate Partial Prostate Brachytherapy as Salvage Treatment for Local Failures After Previous External Beam Radiotherapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03246802
• Other study ID #: H17-01641
• Status: Recruiting
• Phase: N/A
• Start date: January 1, 2018
• Est. completion date: December 31, 2027

Study information

• Verified date: December 2023
• Source: British Columbia Cancer Agency
• Contact: Juanita Crook, MD
• Phone: 2507123958
• Email: jcrook[@]bccancer.bc.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A dose-response relationship for radiation in the management of prostate cancer is well established. Local recurrence of prostate cancer after external beam radiotherapy occurs in at least 40% of patients treated because of inability to deliver sufficient dose through external beam techniques. These patients respond well to re-irradiation using brachytherapy with about 50% of selected patients remaining free of recurrence 5 years after salvage. Advanced imaging using multiparametric Magnetic Resonance Imaging (mpMRI) allows identification of the site of recurrence, permitting partial prostate salvage brachytherapy. There is extensive literature on Low Dose Rate salvage brachytherapy but less on High Dose Rate.

Description:

Appropriately selected patients with histologically documented recurrence 3 years or more after initial external beam radiotherapy will undergo mpMRI for identification of the site of recurrence. A planning transrectal ultrasound (TRUS) will be obtained for fusion with the mpMRI and transposition of the target volume (GTV=gross tumor volume). A margin of 4.5 cm will be added to the GTV to create a focal planning target volume (PTV). The margin may be cropped at the interface with critical organs. Two fractions of HDR brachytherapy will be delivered, each from a single implant, 2 weeks apart. Following treatment patients will be monitored for toxicity and quality of life using the Expanded Prostate cancer Index (EPIC) questionnaire as well as the International Prostate Symptom score. Efficacy will be evaluated by monitoring the Prostate Specific Antigen (PSA) and repeat mpMRI at 2 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 31, 2027
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 45 Years to 80 Years

Eligibility

Inclusion Criteria:

• Age >45 and Life expectancy >10 years

• Previous External Beam Radiotherapy (EBRT) dose up to 78Gray/39 fractions, 81 Gray/45 fractions or 70 Gray/28 fractions

• > 3 year interval since EBRT

• No late toxicity from prior EBRT > grade 2

• Rising PSA post EBRT > nadir + 2 ng/ml but < 10 ng/ml

• PSA Doubling time > 6 months

• Negative staging with CT scan of the abdomen/pelvis and bone scan

• Able to undergo multiparametric MRI with endorectal coil

• Radiographic evidence of dominant intraprostatic lesion (DIL) as only area of recurrence (i.e unifocal recurrence) and corresponding to site of original disease

• Biopsy confirmation of DIL with pathology review by British Columbia Cancer Agency GenitoUrinary pathologist (TB)

• Willing to provide informed consent

• History and physical examination within 90 days of registration

• ECOG performance status 0-1 prior to registration

• IPSS < 16, or adequate voiding study (post void residual < 100cc and peak flow rate > 10 cc/second).

• No prior trans urethral prostatic resection

• Recurrence suitable for implant with HDR brachytherapy as assessed on ultrasound simulation (maximum PTV ideally < 65% of prostate volume)

• No history of inflammatory bowel disease or previous rectal surgery

• Suitable for procedure under anesthesia, spinal or general

• INR <2.5 and platelet count >75 x 109/L

• Androgen Deprivation Therapy may be initiated at the discretion of the treating oncologist

Exclusion Criteria:

• Not compliant with criteria above

• Unable to give informed consent

Related Conditions & MeSH terms

• Prostatic Neoplasms
• Recurrent Prostate Cancer

Intervention

Radiation:
• HDR partial prostate brachytherapy
temporary radioactive implant

Locations

Country	Name	City	State
Canada	BCCA Center for the Southern Interior	Kelowna	British Columbia

Sponsors (1)

Lead Sponsor	Collaborator
British Columbia Cancer Agency

Country where clinical trial is conducted

Canada, 

References & Publications (6)

Arrayeh E, Westphalen AC, Kurhanewicz J, Roach M 3rd, Jung AJ, Carroll PR, Coakley FV. Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):e787-93. doi: 10.1016/j.ijrobp.2011.11.030. Epub 2012 Feb 11. — View Citation

Banerjee R, Park SJ, Anderson E, Demanes DJ, Wang J, Kamrava M. From whole gland to hemigland to ultra-focal high-dose-rate prostate brachytherapy: A dosimetric analysis. Brachytherapy. 2015 May-Jun;14(3):366-72. doi: 10.1016/j.brachy.2014.12.007. Epub 2015 Feb 10. — View Citation

Crook J, Ots A, Gaztanaga M, Schmid M, Araujo C, Hilts M, Batchelar D, Parker B, Bachand F, Milette MP. Ultrasound-planned high-dose-rate prostate brachytherapy: dose painting to the dominant intraprostatic lesion. Brachytherapy. 2014 Sep-Oct;13(5):433-41. doi: 10.1016/j.brachy.2014.05.006. Epub 2014 Jun 20. — View Citation

Da Rosa MR, Milot L, Sugar L, Vesprini D, Chung H, Loblaw A, Pond GR, Klotz L, Haider MA. A prospective comparison of MRI-US fused targeted biopsy versus systematic ultrasound-guided biopsy for detecting clinically significant prostate cancer in patients on active surveillance. J Magn Reson Imaging. 2015 Jan;41(1):220-5. doi: 10.1002/jmri.24710. Epub 2014 Jul 21. — View Citation

Mason J, Al-Qaisieh B, Bownes P, Thwaites D, Henry A. Dosimetry modeling for focal high-dose-rate prostate brachytherapy. Brachytherapy. 2014 Nov-Dec;13(6):611-7. doi: 10.1016/j.brachy.2014.06.007. Epub 2014 Jul 29. — View Citation

Rose JN, Crook JM, Pickles T, Keyes M, Morris WJ. Salvage low-dose-rate permanent seed brachytherapy for locally recurrent prostate cancer: Association between dose and late toxicity. Brachytherapy. 2015 May-Jun;14(3):342-9. doi: 10.1016/j.brachy.2015.01.002. Epub 2015 Feb 26. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Late adverse gastrointestinal or genitourinary events grade 3 or higher	Common Terminology Criteria for Adverse Events (CTCAE V4.0)	3-60 months
Secondary	Late Quality of Life	Expanded Prostate Cancer Index (EPIC)	3-60 months
Secondary	Late lower urinary tract symptoms	International Prostate Symptom Score	3-60 months
Secondary	Acute grade 3 or higher gastrointestinal or genitourinary adverse events	Common Terminology Criteria for Adverse Events (CTCAE V4.0)	0-3 months
Secondary	Acute Quality of Life changes	Expanded Prostate Cancer Index (EPIC)	0-3 months
Secondary	Acute lower urinary symptoms	International Prostate Symptoms Score	0-3 months
Secondary	Biochemical disease free survival	PSA < 0.4 ng/ml at 60 months	60 months